{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:27:06Z","timestamp":1783488426497,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","award":["FK-20-031"],"award-info":[{"award-number":["FK-20-031"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII5_170929"],"award-info":[{"award-number":["CRSII5_170929"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omton.2024.200821","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:48:58Z","timestamp":1716997738000},"page":"200821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["DARPin-fused T\u00a0cell engager for adenovirus-mediated cancer therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Patrick C.","family":"Freitag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kolibius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja","family":"Wieboldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Patricia","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Gogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Br\u00fccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"L\u00e4ubli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pl\u00fcckthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200821_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omton.2024.200821_bib2","doi-asserted-by":"crossref","first-page":"e1450710","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2024.200821_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1078155215618770","article-title":"A review of blinatumomab, a novel immunotherapy","volume":"22","author":"Newman","year":"2016","journal-title":"J.\u00a0Oncol. Pharm. Pract."},{"key":"10.1016\/j.omton.2024.200821_bib4","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015800118","article-title":"Neural stem cells secreting bispecific T\u00a0cell engager to induce selective antiglioma activity","volume":"118","author":"Pituch","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200821_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2024.200821_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200821_bib7","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200821_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2024.200821_bib9","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T\u00a0cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200821_bib10","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omton.2024.200821_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omton.2024.200821_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-cancerbio-070620-104325","article-title":"Targeting solid tumors with bispecific T\u00a0cell engager immune therapy","volume":"6","author":"Arvedson","year":"2022","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.omton.2024.200821_bib13","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2024.200821_bib14","doi-asserted-by":"crossref","first-page":"e006915","DOI":"10.1161\/JAHA.117.006915","article-title":"Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies","volume":"6","author":"Florido","year":"2017","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.omton.2024.200821_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omton.2024.200821_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2024.200821_bib17","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200821_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omton.2024.200821_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-021-01075-5","article-title":"Oncolytic viruses encoding bispecific T\u00a0cell engagers: a blueprint for emerging immunovirotherapies","volume":"14","author":"Heidbuechel","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omton.2024.200821_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.omtm.2021.01.002","article-title":"iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy","volume":"20","author":"Br\u00fccher","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200821_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T\u00a0cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200821_bib22","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.3390\/cancers14112769","article-title":"HydrAd: A helper-dependent adenovirus targeting multiple immune pathways for cancer immunotherapy","volume":"14","author":"Rosewell Shaw","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200821_bib23","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1213653110","article-title":"Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters","volume":"110","author":"Dreier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200821_bib24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jmb.2010.10.040","article-title":"Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting","volume":"405","author":"Dreier","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omton.2024.200821_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200821_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017925118","article-title":"The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody","volume":"118","author":"Smith","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200821_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib7030035","article-title":"Relative contribution of framework and CDR regions in antibody variable domains to multimerisation of Fv- and scFv-containing bispecific antibodies","volume":"7","author":"Bhatta","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.omton.2024.200821_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2024.200821_bib29","first-page":"1369","article-title":"DARPins stack up as anti-COVID-19 agents Nat.","volume":"38","year":"2020","journal-title":"Biotechnol."},{"key":"10.1016\/j.omton.2024.200821_bib30","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nbt1127","article-title":"Engineering novel binding proteins from nonimmunoglobulin domains","volume":"23","author":"Binz","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2024.200821_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/cbic.200300762","article-title":"Consensus design of repeat proteins","volume":"5","author":"Forrer","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.omton.2024.200821_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy","volume":"55","author":"Pl\u00fcckthun","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omton.2024.200821_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40259-020-00429-8","article-title":"Beyond antibodies: the DARPin(\u00ae) drug platform","volume":"34","author":"Stumpp","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.omton.2024.200821_bib34","doi-asserted-by":"crossref","first-page":"2195517","DOI":"10.1080\/19420862.2023.2195517","article-title":"\u201cStapling\u201d scFv for multispecific biotherapeutics of superior properties","volume":"15","author":"Boucher","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2024.200821_bib35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jmb.2007.03.028","article-title":"A designed ankyrin repeat protein evolved to picomolar affinity to Her2","volume":"369","author":"Zahnd","year":"2007","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omton.2024.200821_bib36","doi-asserted-by":"crossref","first-page":"289ra282","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T\u00a0cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2024.200821_bib37","doi-asserted-by":"crossref","first-page":"e24739","DOI":"10.1371\/journal.pone.0024739","article-title":"Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF","volume":"6","author":"Bj\u00f6rkelund","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2024.200821_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antib9030032","article-title":"Improving receptor-mediated intracellular access and accumulation of antibody therapeutics - the tale of HER2","volume":"9","author":"Leyton","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.omton.2024.200821_bib39","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ajpath.2013.07.015","article-title":"Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients","volume":"183","author":"Onsum","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omton.2024.200821_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2024.200821_bib41","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/ijms21103643","article-title":"High-capacity adenoviral vectors: expanding the scope of gene therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2024.200821_bib42","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.2c00346","article-title":"Modular adapters utilizing binders of different molecular types expand cell-targeting options for adenovirus gene delivery","volume":"33","author":"Freitag","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omton.2024.200821_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2023.02.012","article-title":"Targeted adenovirus-mediated transduction of human T\u00a0cells in\u00a0vitro and in\u00a0vivo","volume":"29","author":"Freitag","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200821_bib44","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.ymthe.2023.08.018","article-title":"FAP-retargeted Ad5 enables in\u00a0vivo gene delivery to stromal cells in the tumor microenvironment","volume":"31","author":"Hartmann","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200821_bib45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200821_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in\u00a0vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.omton.2024.200821_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.omton.2024.200821_bib48","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.str.2013.08.020","article-title":"Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2","volume":"21","author":"Jost","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.omton.2024.200821_bib49","doi-asserted-by":"crossref","first-page":"1871171","DOI":"10.1080\/19420862.2020.1871171","article-title":"One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics","volume":"13","author":"Chen","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2024.200821_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/jmbi.1999.3196","article-title":"Selection for improved protein stability by phage display","volume":"294","author":"Jung","year":"1999","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omton.2024.200821_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jmb.2005.01.053","article-title":"Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability","volume":"347","author":"R\u00f6thlisberger","year":"2005","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omton.2024.200821_bib52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","article-title":"Stability engineering of antibody single-chain Fv fragments","volume":"305","author":"W\u00f6rn","year":"2001","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omton.2024.200821_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omton.2024.200821_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cytogfr.2020.10.007","article-title":"Cytokines in oncolytic virotherapy","volume":"56","author":"Pol","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.omton.2024.200821_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200821_bib56","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.97.3.1002","article-title":"Optimization of the helper-dependent adenovirus system for production and potency in\u00a0vivo","volume":"97","author":"Sandig","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2024.200821_bib57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nprot.2009.4","article-title":"A rapid protocol for construction and production of high-capacity adenoviral vectors","volume":"4","author":"Jager","year":"2009","journal-title":"Nat. Protoc."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:16Z","timestamp":1778938636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950329924000638"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200821","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DARPin-fused T\u00a0cell engager for adenovirus-mediated cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"200821"}}